FT-1518 (C09-1133-895)

FT-1518 is a new generation selective, potent and oral bioavailable mTORC1 and mTORC2 inhibitor, and exhibits antitumor activity.In VitroFT-1518 is a new generation selective, potent and oral bioavailable mTORC1 and mTORC2 inhibitor, and exhibits antitumor activity. FT-1518 displays significant growth inhibitory activity against a large panel of hematologic and solid tumor cell lines with most activities falling into low nanomolar range. FT-1518 cuases potent inhibition of the mTOR pathway biomarkers (mTORC 1 & 2 biomarkers [pAkt(S473) and pS6(S240/244) or p70 S6K), no inhibition of PI3K biomarker [pAkt(T308)] in cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoFT-1518 exhibits dose-dependent and higher tumor growth inhibition (TGI) in multiple solid tumor xenografts . MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:SolidIC50& Target:mTORC1 mTORC2. Specification: 0.98 Molecular Formula: C20H26N8O Molecular Weight: 394.47 PubChem CID: 53258965 Isomeric SMILES: CCC(CC)N1C=NC2=C(N=C(N=C21)N3CC4CCC(C3)O4)C5=CN=C(C=N5)N